Copertina

Marginal Zone Lymphoma: Treatment Update With a Focus on Systemic Approaches

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autore principale:	Sonali M. Smith
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Hematological Oncology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Nodular Lymphocyte‐Predominant Hodgkin Lymphoma: Update on Biology and Treatment
di: Peter Borchmann, et al.
Pubblicazione: (2025)

Clinicopathological Characteristics of Extranodal Marginal Zone Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT‐Lymphoma) of the Intestine: A Single Center Analysis
di: Oskar Steinbrecher, et al.
Pubblicazione: (2024)

Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study
di: Pallawi Torka, et al.
Pubblicazione: (2025)

RETRACTION: Burkitt Lymphoma Versus Diffuse Large B‐Cell Lymphoma: A Practical Approach
Pubblicazione: (2026)

Molecular Features of Diffuse Large B‐Cell Lymphoma Associated With Primary Treatment Resistance
di: Allison M. Bock, et al.
Pubblicazione: (2024)

First Line Therapy in Mantle Cell Lymphoma—The Role of BTKi in the Initial Treatment of Transplant‐Eligible and ‐Ineligible Patients
di: E. Silkenstedt, et al.
Pubblicazione: (2025)

Ibrutinib With Bendamustine and Rituximab for Treatment of Patients With Relapsed/Refractory Aggressive B‐Cell Lymphoma
di: Meirav Kedmi, et al.
Pubblicazione: (2024)

Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B‐Cell Lymphoma
di: Juliette Penichoux, et al.
Pubblicazione: (2025)

Lifetime Treatment Trajectories of Mantle Cell Lymphoma: Simulation Based Analysis of 20 Years of Real‐World Data
di: Minna Harmanen, et al.
Pubblicazione: (2025)

Peripheral T‐Cell Lymphoma: What's Next?
di: Sang Eun Yoon, et al.
Pubblicazione: (2025)

Treatments and Outcomes of Newly Diagnosed CD5‐Positive Diffuse Large B‐Cell Lymphoma: A Multi‐Institutional Observational Study
di: Yuma Nato, et al.
Pubblicazione: (2025)

Current Status of Revisions to the Lugano Classification in Lymphoma
Pubblicazione: (2025)

Genetic and Transcriptomic Profiles Identify Potential Therapeutic Targets of Concurrent Follicular and Diffuse Large B‐Cell Lymphoma and Transformed Follicular Lymphoma
di: Rui Sun, et al.
Pubblicazione: (2026)

Follicular Lymphoma: Current Therapeutic Landscape and Future Prospects
di: Emil Kumar, et al.
Pubblicazione: (2025)

Lomustine, Etoposide and Cyclophosphamide as Conditioning for Auto‐HCT in Lymphomas
di: Rafaella Cabral Samico, et al.
Pubblicazione: (2025)

Liposomal Doxorubicin, Vinblastine and Dacarbazine Plus Consolidation Radiotherapy of Residual Nodal Masses for Frontline Treatment in Older Adults With Advanced Stage Classic Hodgkin Lymphoma: Improved Outcome in a Multi‐Center Real‐Life Study
di: M. Picardi, et al.
Pubblicazione: (2024)

Gemcitabine, Carboplatin, Dexamethasone, and Rituximab Versus High‐Dose Cytarabine‐Based Chemotherapy as Second‐Line Treatments for Relapsed or Refractory Diffuse Large B‐Cell Lymphoma
di: Yoshikazu Ikoma, et al.
Pubblicazione: (2025)

Ibrutinib Dose Adjustment Does Not Impair Treatment Outcome in Mantle Cell Lymphoma: An Italian Real‐Life Multicenter Experience. Results From the REDOT_MCL Study
di: Francesca Maria Quaglia, et al.
Pubblicazione: (2026)

Advancing Mantle Cell Lymphoma Risk Assessment: Navigating a Moving Target
di: Simone Ferrero, et al.
Pubblicazione: (2025)

Review of the Management of Relapsed/Refractory Follicular Lymphoma: An Italian Perspective
di: Giacomo Loseto, et al.
Pubblicazione: (2025)

Breaking Traditions: Evaluating Single Fraction Radiation in Indolent Lymphoma
di: Hazim S. Ababneh, et al.
Pubblicazione: (2024)

Indolent T‐Cell Lymphoma of the Gastrointestinal Tract Associated With Strongyloides Stercoralis Infection
di: Yue Zhao, et al.
Pubblicazione: (2025)

CAR T‐Cell Therapies for Patients With Relapsed and Refractory Aggressive Lymphomas: Real‐World Experiences From a Single Center on the Use of Radiotherapy
di: J.T. Jutzi, et al.
Pubblicazione: (2025)

Knockdown of VDAC1 Promotes Ferroptosis in Diffuse Large B‐Cell Lymphoma
di: Chuanming Lin, et al.
Pubblicazione: (2025)

Discovery Science highlights from the 17th International Conference on Malignant Lymphoma
di: Gabriela Forestieri, et al.
Pubblicazione: (2024)

Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study
di: Alessandra Iurlo, et al.
Pubblicazione: (2025)

Early Detection and Central Nervous System Prophylaxis in Patients With High‐Risk Features of Primary Lymphoma of the Female Genital Tract: The Key to Improved Prognosis
di: Bingyi Wang, et al.
Pubblicazione: (2025)

Correction to “Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B‐Cell Lymphoma: A Perspective From an Ad Hoc Panel of Italian Experts”
Pubblicazione: (2025)

Adaptation and Performance of the Self‐Report‐Generated Charlson Comorbidity Index in the Lymphoma Epidemiology of Outcomes (LEO) Cohort
di: James R. Cerhan, et al.
Pubblicazione: (2025)

A SWOT‐Consensus for CAR‐T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection
di: Monia Marchetti, et al.
Pubblicazione: (2025)

Outcome of Adult Lymphoblastic Lymphoma Patients Treated in the Real Life According to the Gimema LAL1913 Protocol: A Campus ALL Multicenter Study
di: M. Delia, et al.
Pubblicazione: (2025)

Causal Associations of Gut Microbiota Species With Lymphoma: A Two‐Sample Mendelian Randomization Study
di: Mei Li, et al.
Pubblicazione: (2025)

Late Cardiac Toxicity After Anthracyclines and Radiotherapy for Lymphoma—A Regression Analysis of Dose‐Response
di: Lotte Nygård, et al.
Pubblicazione: (2025)

MerTK is Ectopically Expressed and Affects the Biological Function in Diffuse Large B‐Cell Lymphoma
di: Yan Li, et al.
Pubblicazione: (2025)

Upregulated miR‐29a‐3p Prevent Malignant Features of Lymphoma Cells by Targeting MCL1
di: Tengfei Shi, et al.
Pubblicazione: (2025)

Real‐life study on the use of response adapted therapy in patients with Hodgkin Lymphoma: Results from a multicenter experience
di: Vittorio Ruggero Zilioli, et al.
Pubblicazione: (2024)

Exploratory Analysis of Practical Predictive Indices for the Efficacy of Mogamulizumab in Patients With Aggressive Adult T‐Cell Leukemia‐Lymphoma
di: Yutaka Shimazu, et al.
Pubblicazione: (2025)

Toxicity and Tolerability of the OEPA/COPDAC Regimen in Children and Adolescents With Hodgkin Lymphoma: A Real‐World Experience
di: Hala Bekhit, et al.
Pubblicazione: (2025)

Changes in Lean Muscle Mass, Muscle Strength, and Physical Performance Following First‐Line Chemotherapy in Patients With Lymphoma
di: Charlotte Nørregaard Grønset, et al.
Pubblicazione: (2025)

Polatuzumab Vedotin and Glofitamab for Relapsed/Refractory Diffuse Large B‐Cell Lymphoma in the Compassionate Use Program in Italy
di: Pier Luigi Zinzani, et al.
Pubblicazione: (2025)